Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07569757 TQB2934 Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07569757 clinical trial report covering TQB2934, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Elotuzumab Biologics Sequence Review Report 2026: SLAMF7 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Elotuzumab, an antibody targeting SLAMF7.
Latest Hotspot
8 min read
NCT07570316 Efgartigimod/Hyaluronidase Graves Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07570316 clinical trial report covering Efgartigimod/Hyaluronidase, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07569536 Dexmedetomidine Hydrochloride Shock, Septic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07569536 clinical trial report covering Dexmedetomidine Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-UMIN000061476 Alectinib Hydrochloride ALK positive Non-Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
JPRN-UMIN000061476 clinical trial report covering Alectinib Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Mezagitamab Biologics Sequence Review Report 2026: CD38 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mezagitamab, an antibody targeting CD38.
Latest Hotspot
8 min read
NCT07573176 Seltorexant Depressive Disorder, Major Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07573176 clinical trial report covering Seltorexant, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07573969 Bupivacaine Hydrochloride Analgesia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07573969 clinical trial report covering Bupivacaine Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Felzartamab Biologics Sequence Review Report 2026: CD38 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Felzartamab, an antibody targeting CD38.
Latest Hotspot
8 min read
NCT07573462 Multivalent Pneumococcal Conjugate Vaccine(Pfizer) Pneumococcal Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07573462 clinical trial report covering Multivalent Pneumococcal Conjugate Vaccine(Pfizer), Phase 3, endpoints, sponsor, geography, readout timing and deve
Latest Hotspot
8 min read
CTR20261709 Pimavanserin tartrate Parkinson Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
CTR20261709 clinical trial report covering Pimavanserin tartrate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Isatuximab Biologics Sequence Review Report 2026: CD38 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Isatuximab, an antibody targeting CD38.